ARA-290 10mg

Research

Scientific Research on ARA‑290 (Cibinetide)

ARA‑290 (also known as Cibinetide) is a synthetic 11‑amino‑acid peptide derived from the secondary‑structure helix‑B region of erythropoietin (EPO). Its key scientific interest lies in the ability to separate the neuroprotective and anti‑inflammatory effects of EPO from its hematopoietic (erythropoietic) actions.

Unlike native EPO, ARA‑290 does not bind the erythropoietin homodimer receptor (EPOR₂), so it avoids stimulating red‑blood‑cell production while still engaging the “innate repair receptor” (IRR), a heterocomplex of EPOR plus the common‑beta receptor (CD131/βcR).

Mechanism of Action and Inhibition (if applicable)

The central mechanism of ARA‑290 is activation of the innate repair receptor (IRR), triggering anti‑inflammatory and anti‑apoptotic signaling cascades, primarily via JAK2/STAT5 and PI3K/Akt pathways.

This leads to downregulation of pro‑inflammatory cytokines such as TNF‑α, IL‑6, and MCP‑1, and to inhibition of NF‑κB nuclear translocation, the master regulator of inflammatory gene expression, thereby reducing tissue‑level oxidative stress.

No specific small‑molecule or receptor antagonist that “blocks ARA‑290” itself is widely reported in the literature; however, pharmacological or genetic disruption of the IRR complex (for example, targeting βcR or downstream JAK/STAT or PI3K/Akt elements) would be expected to blunt its biological effects.

Effects on Metabolism and Nervous‑System Function

Clinical and preclinical work has particularly focused on metabolic and neuropathic conditions:

• Small‑fiber neuropathy (SFN): In type‑2 diabetes and sarcoidosis‑associated SFN, ARA‑290 increases intraepidermal nerve fiber density and corneal nerve fiber abundance, improves quantitative sensory‑testing thresholds, and reduces neuropathic‑pain scores, suggesting a disease‑modifying, regenerative role rather than purely symptomatic relief.
• Pancreatic islet protection: In islet‑transplant models, ARA‑290 reduces cytokine‑mediated β‑cell apoptosis, helping to preserve islet‑graft function and post‑operative glycemic control.
• Insulin resistance and low‑grade inflammation: By reducing systemic inflammation, the peptide may improve peripheral insulin‑sensitivity markers, although these effects are still being characterized.

Investigation in oncological and chemotherapy‑related settings

Because native EPO can promote tumor growth via EPOR₂ on many cancers, long‑term EPO use in oncology has been limited. ARA‑290, lacking EPOR₂ binding, is considered a safer candidate for managing complications in cancer‑related care:

• Chemotherapy‑induced peripheral neuropathy (CIPN): ARA‑290 is being explored as a neuroprotective agent against nerve damage caused by agents such as cisplatin and paclitaxel, aiming to preserve small‑fiber integrity without stimulating neoplastic proliferation.
• No robust evidence yet supports ARA‑290 as a direct antitumor drug; current data focus on neuroprotection and quality‑of‑life support in oncology‑related neuropathies.

Pharmacokinetics in research

ARA‑290 is typically administered subcutaneously or intravenously in experimental and early‑phase protocols. It has a very short plasma half‑life in humans (around 2–5 minutes), but its biological effects can persist due to prolonged activation of intracellular signaling cascades after IRR engagement (“hit‑and‑run” kinetics). The peptide is degraded by endogenous peptidases into constituent amino acids, resulting in low risk of cumulative toxicity or complex cytochrome‑P450‑mediated drug interactions.

Other relevant research contexts

• Sarcoidosis‑related neuropathy: Phase‑II and subsequent trials showed that daily subcutaneous ARA‑290 significantly improves neuropathic symptoms, corneal‑nerve‑fiber density, exercise capacity, and quality of life in sarcoidosis patients with small‑fiber neuropathy, with a favorable safety profile.
• Ischemia–reperfusion injury: In models of renal and myocardial ischemia, ARA‑290 reduced infarct size and subsequent fibrosis by activating the IRR during the ischemic event, highlighting its role in organ‑protection research.
• Diabetic retinopathy: In diabetic rodent models, ARA‑290 reduces retinal thinning, retinal‑inflammatory stimuli, and immune‑cell activation, preserving neural‑retinal structure and function, consistent with its broader neuroprotective and anti‑inflammatory profile.

Final considerations

ARA‑290 represents a precision‑medicine advance in pharmacology by isolating EPO’s tissue‑repair and anti‑inflammatory properties from its hematopoietic effects. For researchers, it is a robust tool for studying the innate repair receptor system and for exploring therapies in chronic‑inflammatory and neurodegenerative conditions, especially SFN‑related and metabolic‑neural disorders. Although early‑phase clinical data are encouraging, large‑scale phase‑III studies are needed before broad therapeutic adoption, and long‑term safety and optimal dosing regimens remain active research questions.

References

• Brines, M., Dunne, A. N., van Velzen, M., et al. (2014). ARA 290, a nonerythropoietic peptide engineered from erythropoietin, ameliorates inflammatory cytokine production and neuropathic pain. Molecular Medicine, 20(1).
• Dahan, A., Dunne, A., Swartjes, M., et al. (2013). ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Clinical Therapeutics, 35(6).
• Heij, L., Niesters, M., Swartjes, M., et al. (2012). Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double‑blind, pilot study. Molecular Medicine, 18(1).
• Ciaramella, A., Mantegna, G., Niwa, H., et al. (2021). The Innate Repair Receptor (IRR) System: A Review of its Role in Inflammation and Tissue Repair. Frontiers in Pharmacology, 12.
• PubChem entry for ARA‑290 (Cibinetide) – CID: 91810664 (molecular formula C₅₁H₈₄N₁₆O₂₁, MW 1257.3 g/mol).